- Home
- JNJ
as 11-03-2025 3:55pm EST
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
| Founded: | 1886 | Country: | United States |
| Employees: | N/A | City: | NEW BRUNSWICK |
| Market Cap: | 449.6B | IPO Year: | 1944 |
| Target Price: | $196.19 | AVG Volume (30 days): | 8.4M |
| Analyst Decision: | Buy | Number of Analysts: | 16 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 10.35 | EPS Growth: | 71.26 |
| 52 Week Low/High: | $140.68 - $194.48 | Next Earning Date: | 10-14-2025 |
| Revenue: | $92,149,000,000 | Revenue Growth: | 5.08% |
| Revenue Growth (this year): | 6.63% | Revenue Growth (next year): | 5.31% |
Stock Insider Trading Activity of Johnson & Johnson (JNJ)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| REED JOHN C | JNJ | EVP, Innovative Medicine, R&D | Oct 17 '25 | Sell | $192.71 | 21,721 | $4,185,793.09 | 10,658 | |
| Taubert Jennifer L | JNJ | EVP, WWC. Innovative Medicine | Sep 4 '25 | Sell | $177.81 | 56,471 | $10,040,882.63 | 178,013.001 | |
| Duato Joaquin | JNJ | CEO and Chairman of the Board | Aug 22 '25 | Sell | $179.21 | 125,824 | $22,548,654.81 | 275,967 | |
| Wolk Joseph J | JNJ | Exec VP, CFO | Aug 15 '25 | Sell | $176.91 | 16,820 | $2,975,570.69 | 14,000 |
Latest Johnson & Johnson News
JNJ Breaking Stock News: Dive into JNJ Ticker-Specific Updates for Smart Investing
Barrons.com
7 hours ago
Kimberly-Clark to Buy Tylenol Maker Kenvue. Why Kimberly-Clark Stock Is Tanking.
USA TODAY
8 hours ago
Kimberly-Clark to buy Kenvue, maker of Tylenol, in $48 billion deal
Quartz
9 hours ago
Kimberly-Clark buys Tylenol maker Kenvue for more than $48 billion
The Wall Street Journal
9 hours ago
Kimberly-Clark Strikes $40 Billion Deal for Tylenol Maker Kenvue
Associated Press Finance
10 hours ago
Tylenol, Kleenex, Band-Aid and more put under one roof in $48.7 billion consumer brands deal
GlobeNewswire
10 hours ago
Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
WWD
10 hours ago
Kimberly-Clark to Acquire Kenvue
GlobeNewswire
10 hours ago
Japan Non-Invasive Aesthetic Treatment Market Analysis and Outlook 2025-2033 with City-Level Breakdowns by Procedure, Gender and End User
Compare JNJ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JNJ Johnson & Johnson - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.